1.04

7.68% 0.0742

After Hours: 1.04

Atyr Pharma Inc (ATYR)

Overview News Price History Discussions Forecast

Atyr Pharma Inc stock is traded at $1.04, with a volume of 8.23M. It is up +7.68% in the last 24 hours and down -82.75% over the past month. aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Previous Close:

$0.9658

Open:

$0.92435

24h Volume:

8.23M

Relative Volume:

0.76

Market Cap:

$101.91M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+24.36%

1M Performance:

-82.75%

6M Performance:

-65.45%

1Y Performance:

-53.57%

1-Day Range:

$0.90

$1.06

1-Week Range:

$0.8101

$1.12

52-Week Range:

$0.6816

$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Name

Atyr Pharma Inc

Sector

Healthcare (1140)

Industry

Biotechnology (636)

Phone

(858) 731-8389

Address

10240 SORRENTO VALLEY ROAD, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ATYR's Discussions on Twitter

Compare ATYR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATYR Atyr Pharma Inc	1.04	94.64M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	412.22	104.45B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	469.36	60.95B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	572.60	59.11B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	812.95	49.23B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.94	35.92B	4.56B	-176.77M	225.30M	-1.7177

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-16-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-15-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-15-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-18-25	Initiated	Leerink Partners	Outperform
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Oct-04-24	Initiated	Wells Fargo	Overweight
Sep-05-24	Initiated	Jefferies	Buy
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform
Sep-21-21	Initiated	Piper Sandler	Overweight
May-10-21	Initiated	Laidlaw	Buy
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-04-20	Initiated	ROTH Capital	Buy
Mar-02-20	Initiated	Oppenheimer	Outperform
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	Citigroup	Buy
Jun-01-15	Initiated	JP Morgan	Overweight

View All

Atyr Pharma Inc Stock (ATYR) Latest News

Oct 14, 2025

ATYR ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire

Oct 14, 2025

ATyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman - Barchart.com

Oct 14, 2025

What makes aTyr Pharma Inc. (471A) stock appealing to growth investorsMarket Activity Recap & Real-Time Stock Entry Alerts - newser.com

Oct 14, 2025

Oct 13, 2025

Should You Reconsider aTyr Pharma After the Recent 17% Price Surge? - simplywall.st

Oct 13, 2025

Levi & Korsinsky Notifies aTyr Pharma, Inc. (ATYR) InvestorsLead Plaintiff Deadline on December 8, 2025 - ACCESS Newswire

Oct 13, 2025

aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman - GlobeNewswire

Oct 13, 2025

Contact The Gross Law Firm by December 8, 2025 Deadline to Join Class Action Against aTyr Pharma, Inc. (ATYR) - GlobeNewswire

Oct 13, 2025

Contact The Gross Law Firm by December 8, 2025 Deadline to Join Class Action Against aTyr Pharma, Inc. (ATYR) - GlobeNewswire Inc.

Oct 13, 2025

Detecting support and resistance levels for aTyr Pharma Inc.2025 Volatility Report & Growth-Oriented Investment Plans - newser.com

Oct 13, 2025

What catalysts could drive aTyr Pharma Inc. stock higherQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com

Oct 13, 2025

Recover Investment Losses: Class Action Initiated Against aTyr Pharma, Inc. (ATYR) - ACCESS Newswire

Oct 13, 2025

Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire

Oct 13, 2025

Is aTyr Pharma Inc. (471A) stock among top earnings playsEarnings Miss & Community Supported Trade Ideas - newser.com

Oct 13, 2025

Will aTyr Pharma Inc. outperform the market2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com

Oct 13, 2025

Statistical indicators supporting aTyr Pharma Inc.’s strengthRate Cut & Community Trade Idea Sharing - newser.com

Oct 13, 2025

Why aTyr Pharma Inc. stock could see breakout soonStock Surge & Scalable Portfolio Growth Ideas - newser.com

Oct 13, 2025

Oct 12, 2025

Levi & Korsinsky Urges aTyr Pharma, Inc. (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - ACCESS Newswire

Oct 12, 2025

Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - ACCESS Newswire

Oct 12, 2025

ATYR LAWSUIT ALERT: Levi & Korsinsky Notifies aTyr Pharma, Inc. InvestorsLead Plaintiff Deadline December 8, 2025 - ACCESS Newswire

Oct 12, 2025

aTyr Pharma Sees Significant Rebound in Premarket Trading - timothysykes.com

Oct 12, 2025

ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Oct 12, 2025

INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - The Globe and Mail

Oct 12, 2025

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr - GlobeNewswire

Oct 12, 2025

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Oct 12, 2025

Insider Spends US$912k Buying More Shares In ATyr Pharma - 富途牛牛

Oct 12, 2025

Independent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares - Yahoo Finance

Oct 12, 2025

Measuring aTyr Pharma Inc.’s beta against major indices2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com

Oct 12, 2025

Oct 11, 2025

aTyr Pharma Rebounds with 7.4% Premarket Surge After Recent Decline - StocksToTrade

Oct 11, 2025

Oct 10, 2025

ATyr Pharma Faces Investor Suit Over Failed Drug Trial - Law360

Oct 10, 2025

Insider Buying: aTyr Pharma (NASDAQ:ATYR) Director Purchases 682,001 Shares of Stock - MarketBeat

Oct 10, 2025

ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc. - GlobeNewswire

Oct 10, 2025

ATyr Pharma, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – ATYR - MarketScreener

Oct 10, 2025

aTyr Pharma, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – ATYR - FinancialContent

Oct 10, 2025

ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The AI Journal

Oct 10, 2025

Levi & Korsinsky Invites Investors to SueWallSt After aTyr Pharma, Inc. Stock Collapse - ACCESS Newswire

Oct 10, 2025

Rosen Law Firm Urges aTyr Pharma, Inc. (NASDAQ: ATYR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - The AI Journal

Oct 10, 2025